Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun 20:4:91-101.
doi: 10.2147/BCTT.S29432.

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer

M Bauer  1 , J Bryce  2 , P Hadji  1
Affiliations
Review

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer

M Bauer et al. Breast Cancer (Dove Med Press). .

Abstract

Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to the risk of bone loss in postmenopausal women with breast cancer. One of the most common and severe safety issues associated with cancer therapy for patients with breast cancer is bone loss and the associated increase in risk of fractures. This paper reviews the recent literature pertaining to aromatase inhibitor (AI)-associated bone loss, and discusses suggested management and preventative approaches that may help patients remain on therapy to derive maximum clinical benefit. A case study is presented to illustrate the discussion. We observed that AIs are in widespread use for women with hormone receptor-positive breast cancer and are now recommended as adjuvant therapy, either as primary therapy or sequential to tamoxifen, for postmenopausal women. AIs target the estrogen biosynthetic pathway and deprive tumor cells of the growth-promoting effects of estrogen, and AI therapies provide benefits to patients in terms of improved disease-free survival. However, there is a concern regarding the increased risk of bone loss with prolonged AI therapy, which can be managed in many cases with the use of bisphosphonates and other interventions (eg, calcium, vitamin D supplementation, exercise).

Keywords: aromatase inhibitors; bisphosphonates; bone loss; breast cancer; estrogen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer treatment-induced bone loss.,,– Abbreviations: AI, aromatase inhibitor; BMD, bone mineral density; GnRH, gonadotropin-releasing hormone; PMw, postmenopausal women.
Figure 2
Figure 2
Left femur bone mass density over time. (A) At baseline, (B) at 12 months, and (C) at 24 months. Note: Bone scans provided by authors.
Figure 3
Figure 3
Right femur bone mass density over time. (A) At baseline, (B) at 12 months, and (C) at 24 months. Note: Bone scans provided by authors.
Figure 4
Figure 4
Lumbar spine bone mass density over time. (A) At baseline, (B) at 12 months, and (C) at 24 months.
See this image and copyright information in PMC

References

    1. Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol. 2010;22:56–60. - PubMed
    1. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69:73–82. - PubMed
    1. Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K. The effect of aromatase inhibitors on bone metabolism. Basic Clin Pharmacol Toxicol. 2008;104:3–10. - PubMed
    1. Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist. 2008;13:829–837. - PubMed
    1. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev. 2010;36:249–261. - PubMed